We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+2.27%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$7.33B
AUM Growth
+$1.08B
Cap. Flow
+$1.18B
Cap. Flow %
16.06%
Top 10 Hldgs %
55.65%
Holding
321
New
63
Increased
80
Reduced
61
Closed
90

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$101M
2
ICLR icon
Icon
ICLR
+$97.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$87.9M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$82.5M
5
GSK icon
GSK
GSK
+$66.7M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$40.5M
2
PTCT icon
PTC Therapeutics
PTCT
+$36.7M
3
SHAK icon
Shake Shack
SHAK
+$32.9M
4
INCY icon
Incyte
INCY
+$30.5M
5
CYTK icon
Cytokinetics
CYTK
+$30.4M

Sector Composition

Rank Sector Weight
1 Healthcare 39.34%
2 Consumer Discretionary 6.39%
3 Consumer Staples 5.37%
4 Technology 5.27%
5 Communication Services 0.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COTY icon
251
Coty
COTY
$2.48B
– –
-911,706
Closed -$8.56M
CPB icon
252
Campbell Soup
CPB
$6.87B
– –
-335,473
Closed -$16.4M
CROX icon
253
Crocs
CROX
$6.55B
– –
-38,130
Closed -$5.52M
CRVO icon
254
CervoMed
CRVO
$26.6M
– –
-402,000
Closed -$5.87M
CTXR icon
255
Citius Pharmaceuticals
CTXR
$18.7M
– –
-291,040
Closed -$3.64M
DOCU
256
DocuSign
DOCU
$11.5B
– –
-402,894
Closed -$25M
EL icon
257
Estee Lauder
EL
$32B
– –
-184,472
Closed -$18.4M
ELDN icon
258
Eledon Pharmaceuticals
ELDN
$285M
– –
-2,364,000
Closed -$5.89M
ENTA icon
259
Enanta Pharmaceuticals
ENTA
$400M
– –
-1,000,000
Closed -$10.4M
EOLS icon
260
Evolus
EOLS
$501M
– –
-360,000
Closed -$5.83M
ETSY icon
261
Etsy
ETSY
$7.85B
– –
-90,164
Closed -$5.01M
HYPD
262
Hyperion DeFi Inc
HYPD
$40.9M
– –
-106,679
Closed -$4.41M
FRPT icon
263
Freshpet
FRPT
$3.22B
– –
-125,713
Closed -$17.2M
GE icon
264
GE Aerospace
GE
$384B
– –
-4,974
Closed -$938K
GIL icon
265
Gildan
GIL
$10.6B
– –
-4,384
Closed -$207K
GXAI
266
Gaxos.ai
GXAI
$9.13M
– –
-22,000
Closed -$35K
HELE icon
267
Helen of Troy
HELE
$693M
– –
-186,000
Closed -$11.5M
PPLI
268
People Inc
PPLI
$3.1B
– –
-7,899
Closed -$349K
IDAI icon
269
T Stamp
IDAI
$18.1M
– –
-39,328
Closed -$130K
IKT icon
270
Inhibikase Therapeutics
IKT
$388M
– –
-626,500
Closed -$814K
ITRM
271
DELISTED
Iterum Therapeutics
ITRM
– –
-1,340,000
Closed -$1.46M
IVDA icon
272
Iveda Solutions
IVDA
$3.54M
– –
-130,000
Closed -$217K
KMB icon
273
Kimberly-Clark
KMB
$36.5B
– –
-2,548
Closed -$363K
KRE icon
274
State Street SPDR S&P Regional Banking ETF
KRE
$4.64B
– –
-9,766
Closed -$553K
LEN icon
275
Lennar Class A
LEN
$21.2B
– –
-20,696
Closed -$3.76M
9 10
11
12 13

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return
ACM
Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return
PI
PGGM Investments Zeist, Netherlands $5.7B AUM 17.05% 1-Year Est. Return

Armistice Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Armistice Capital held 321 positions worth $7.33B, up 17% from $6.25B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Armistice Capital deployed $1.18B of net new capital in Q4 2024, opening 63 new positions and adding to 80 existing holdings. Its largest new stake was Exact Sciences: 1,617,000 shares worth $90.9M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 42% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

On the sell side, the largest reduction was PTC Therapeutics, an estimated $36.7M trimmed.

  • Armistice Capital's largest Q4 2024 buy was Exact Sciences: 1,617,000 shares worth $90.9M.
  • Armistice Capital added most to Neurocrine Biosciences in Q4 2024, an estimated $87.9M increase.
  • Armistice Capital's biggest Q4 2024 reduction was PTC Therapeutics, cutting an estimated $36.7M.
  • Armistice Capital fully exited Alkermes in Q4 2024, selling an estimated $40.5M.
  • Armistice Capital's ten largest holdings make up 56% of its $7.33B portfolio in Q4 2024.
  • Armistice Capital opened 63 new positions and closed 90 in Q4 2024.
  • Armistice Capital's portfolio value rose 17% quarter-over-quarter to $7.33B.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.